| __timestamp | Intra-Cellular Therapies, Inc. | Walgreens Boots Alliance, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 54823000000 |
| Thursday, January 1, 2015 | 139626 | 76691000000 |
| Friday, January 1, 2016 | 93831530 | 87477000000 |
| Sunday, January 1, 2017 | 79419009 | 89052000000 |
| Monday, January 1, 2018 | 368673 | 100745000000 |
| Tuesday, January 1, 2019 | 477121 | 91915000000 |
| Wednesday, January 1, 2020 | 1895029 | 95905000000 |
| Friday, January 1, 2021 | 8034589 | 104442000000 |
| Saturday, January 1, 2022 | 20443000 | 104437000000 |
| Sunday, January 1, 2023 | 33745000 | 112009000000 |
| Monday, January 1, 2024 | 121134000000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of the pharmaceutical and retail sectors, Intra-Cellular Therapies, Inc. and Walgreens Boots Alliance, Inc. present a fascinating study in contrasts. From 2014 to 2023, Walgreens consistently reported a cost of revenue that dwarfed that of Intra-Cellular Therapies, with figures often exceeding 100 billion dollars annually. In contrast, Intra-Cellular Therapies, a smaller player in the pharmaceutical industry, saw its cost of revenue grow from a modest 140,000 dollars in 2015 to over 33 million dollars by 2023. This represents a staggering increase of over 23,000% in less than a decade. While Walgreens' cost of revenue remained relatively stable, Intra-Cellular Therapies' growth trajectory highlights its expanding footprint in the industry. However, data for 2024 is missing for Intra-Cellular Therapies, leaving room for speculation on its future performance.
Analyzing Cost of Revenue: Novo Nordisk A/S and Intra-Cellular Therapies, Inc.
Cost of Revenue: Key Insights for Merck & Co., Inc. and Intra-Cellular Therapies, Inc.
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Intra-Cellular Therapies, Inc.
GSK plc vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
Intra-Cellular Therapies, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Bio-Techne Corporation vs Walgreens Boots Alliance, Inc.
Cost of Revenue: Key Insights for Walgreens Boots Alliance, Inc. and Cytokinetics, Incorporated
Cost Insights: Breaking Down Walgreens Boots Alliance, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Walgreens Boots Alliance, Inc. vs Wave Life Sciences Ltd.
Cost of Revenue Comparison: Walgreens Boots Alliance, Inc. vs Taro Pharmaceutical Industries Ltd.